282 related articles for article (PubMed ID: 35526045)
1. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
[TBL] [Abstract][Full Text] [Related]
2. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Piñana JL; Vazquez L; Calabuig M; López-Corral L; Martin-Martin G; Villalon L; Sanz-Linares G; Conesa-Garcia V; Sanchez-Salinas A; Gago B; Facal A; Risco-Gálvez I; Olave MT; Espigado I; Lopez-Jimenez J; Hernández-Rivas JÁ; Avendaño-Pita A; Arroyo I; Ferrer E; García-Cadenas I; González-Santillana C; Roldán-Pérez A; Ferrer B; Guerreiro M; Suarez-Lledó M; Camara A; Campos-Beltrán D; Navarro D; Cedillo Á; Sureda A; Solano C; ; Martino R
Blood Cancer J; 2023 Jan; 13(1):8. PubMed ID: 36599843
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
4. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
[TBL] [Abstract][Full Text] [Related]
5. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
9. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
Regev-Yochay G; Lustig Y; Joseph G; Gilboa M; Barda N; Gens I; Indenbaum V; Halpern O; Katz-Likvornik S; Levin T; Kanaaneh Y; Asraf K; Amit S; Rubin C; Ziv A; Koren R; Mandelboim M; Tokayer NH; Meltzer L; Doolman R; Mendelson E; Alroy-Preis S; Kreiss Y
Lancet Microbe; 2023 May; 4(5):e309-e318. PubMed ID: 36963419
[TBL] [Abstract][Full Text] [Related]
10. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
Uwamino Y; Kurafuji T; Takato K; Sakai A; Tanabe A; Noguchi M; Yatabe Y; Arai T; Ohno A; Tomita Y; Shibata A; Yokota H; Yamasawa W; Namkoong H; Sato Y; Hasegawa N; Wakui M; Murata M;
Vaccine; 2022 Jul; 40(32):4538-4543. PubMed ID: 35718591
[TBL] [Abstract][Full Text] [Related]
12. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
13. Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs.
Pani A; Cento V; Vismara C; Campisi D; Di Ruscio F; Romandini A; Senatore M; Schenardi PA; Gagliardi OM; Giroldi S; Zoppini L; Moreno M; Corradin M; Epis OM; Ughi N; Cuppari I; Crocchiolo R; Merli M; Bosio M; Rossini S; Puoti M; Scaglione F
Mayo Clin Proc; 2021 Dec; 96(12):2966-2979. PubMed ID: 34736776
[TBL] [Abstract][Full Text] [Related]
14. The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
Gueguen M; Khatchatourian L; Lohéac C; Dorval I; Mercier M; Le Calloch R; Mahé K; Rizcallah MJ; Hutin P; Fangous MS; Saidani N; Le Clech L
Infect Dis Now; 2022 Aug; 52(5):280-285. PubMed ID: 35667558
[TBL] [Abstract][Full Text] [Related]
15. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
16. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP; Schiavetti I; Inglese M; Carmisciano L; Laroni A; Lapucci C; Visconti V; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Cocco E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Pizzorno M; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2022 Jun; 80():104042. PubMed ID: 35526306
[TBL] [Abstract][Full Text] [Related]
18. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
20. Serologic Status According Severe Acute Respiratory Syndrome Coronavirus 2 in Patients After Orthotopic Heart Transplantation.
Kuczaj A; Przybyłowski P
Transplant Proc; 2022 May; 54(4):901-904. PubMed ID: 35414422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
